SCHEMBL3040498

SCHEMBL3040498

CCCCC(C)(CCC)OC=O

nearest known ligand 0.39

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.39
FDPS P14324 1/20 0.33
TSHR P16473 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671770 0.91 TDP1 (0.46) TDP1FDPS
SCHEMBL276523 0.87 TDP1 (0.39) TDP1FDPSTSHR
SCHEMBL27281363 0.87 GGPS1 (0.42) TDP1FDPSTSHR
SCHEMBL27282120 0.87 GGPS1 (0.42) TDP1FDPSTSHR
SCHEMBL4675077 0.82 TDP1 (0.42) TDP1FDPS
SCHEMBL3035858 0.81 TDP1 (0.37) TDP1FDPSTSHR
SCHEMBL16481924 0.79 TDP1 (0.32) TDP1
SCHEMBL93232 0.77 TDP1 (0.42) TDP1FDPSTSHR
SCHEMBL3039795 0.75 TDP1 (0.36) TDP1
Hydrochloric Acid SCHEMBL27905679 0.72 FDPS (0.41) TDP1FDPSTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216736-A2 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-26 US disclosed
US-20100056466-A1 2'-Cyanopyrimidine Nucleoside Compound MATSUDA, AKIRA (JP) 2010-03-04 US disclosed
EP-2045256-A1 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) 2009-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216736-A2 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND NUDT1, DPYD, SLC29A1 TDP1 775/4885FDPS 2126/4885TSHR 2498/4885
US-20100056466-A1 2'-Cyanopyrimidine Nucleoside Compound NUDT1, DPYD, SLC29A1 TDP1 775/4885FDPS 2126/4885TSHR 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.